Continue to site >
Trending ETFs

Name

As of 05/20/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

$22.37

$26.7 M

0.78%

$0.17

0.19%

Vitals

YTD Return

2.4%

1 yr return

7.5%

3 Yr Avg Return

N/A

5 Yr Avg Return

N/A

Net Assets

$26.7 M

Holdings in Top 10

71.5%

52 WEEK LOW AND HIGH

$22.2
$18.24
$22.98

Expenses

OPERATING FEES

Expense Ratio 0.19%

SALES FEES

Front Load N/A

Deferred Load N/A

TRADING FEES

Turnover N/A

Redemption Fee N/A


Min Investment

Standard (Taxable)

N/A

IRA

N/A


Fund Classification

Fund Type

Exchange Traded Fund


Name

As of 05/20/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

$22.37

$26.7 M

0.78%

$0.17

0.19%

IBBQ - Profile

Distributions

  • YTD Total Return 2.4%
  • 3 Yr Annualized Total Return N/A
  • 5 Yr Annualized Total Return N/A
  • Capital Gain Distribution Frequency N/A
  • Net Income Ratio N/A
DIVIDENDS
  • Dividend Yield 0.8%
  • Dividend Distribution Frequency Quarterly

Fund Details

  • Legal Name
    Invesco Nasdaq Biotechnology ETF
  • Fund Family Name
    INVESCOETF
  • Inception Date
    Jun 11, 2021
  • Shares Outstanding
    N/A
  • Share Class
    N/A
  • Currency
    USD
  • Domiciled Country
    US
  • Manager
    Peter Hubbard

Fund Description

The Fund generally will invest at least 90% of its total assets in the securities that comprise the Underlying Index.
Strictly in accordance with its guidelines and mandated procedures, Nasdaq, Inc. (“Nasdaq” or the “Index Provider”) compiles the Underlying Index, which is a modified market-capitalization weighted index that is designed to measure the performance of securities listed on the Nasdaq Stock Market that are classified as either biotechnology or pharmaceutical companies. Eligible securities must (1) be classified under the biotechnology subsector or pharmaceuticals subsector of the Industry Classification Benchmark (“ICB”), (2) have a minimum market capitalization of $200 million at the time of the Underlying Index's annual rebalancing, and (3) have a minimum average daily trading volume of 100,000 shares.
The Underlying Index may include securities of large-, mid- and small-capitalization companies.
As of October 31, 2023, the Underlying Index was comprised of 261constituents with market capitalizations ranging from approximately $192.8billion to $7.7million.
The Underlying Index is rebalanced annually in December and reweighted quarterly, effective at market open of the following trading day after the close of trading on the third Friday in March, June, September and
December. The Fund is rebalanced and reweighted in accordance with the Underlying Index. Securities in the Underlying Index are weighted by market capitalization. At each quarter, Nasdaq reweights the Underlying Index such that the maximum weight of any constituent does not exceed 8%. Only the five largest securities may exceed a 4% cap; the individual weight of all other remaining constituents may not exceed 4%.
The Fund employs a “full replication” methodology in seeking to track the Underlying Index, meaning that the Fund generally invests in all of the securities comprising the Underlying Index in proportion to their weightings in the Underlying Index.
The Fund is “non-diversified” and therefore is not required to meet certain diversification requirements under the  Investment Company Act of 1940, as amended (the “1940 Act”).
Concentration Policy. The Fund will concentrate its investments (i.e., invest 25% or more of the value of its total assets) in securities of issuers in any one industry or group of industries only to the extent that the Underlying Index reflects a concentration in that industry or group of industries. The Fund will not otherwise concentrate its investments in securities of issuers in any one industry or group of industries. As of August 31, 2023, the Fund had significant exposure to the biotechnology industry. The Fund's portfolio holdings, and the extent to which it concentrates its investments, are likely to change over time.
Read More

IBBQ - Performance

Return Ranking - Trailing

Period IBBQ Return Category Return Low Category Return High Rank in Category (%)
YTD 2.4% -25.6% 23.4% 96.65%
1 Yr 7.5% -30.0% 21.8% N/A
3 Yr N/A* -18.7% 19.7% N/A
5 Yr N/A* -14.7% 15.3% N/A
10 Yr N/A* -6.2% 15.7% N/A

* Annualized

Return Ranking - Calendar

Period IBBQ Return Category Return Low Category Return High Rank in Category (%)
2023 3.8% -53.9% 11.7% N/A
2022 -11.1% -22.3% 18.5% N/A
2021 N/A -4.7% 41.4% N/A
2020 N/A -10.2% 13.1% N/A
2019 N/A -5.7% 26.9% N/A

Total Return Ranking - Trailing

Period IBBQ Return Category Return Low Category Return High Rank in Category (%)
YTD 2.4% -41.2% 23.4% 96.09%
1 Yr 7.5% -30.0% 28.3% N/A
3 Yr N/A* -18.7% 19.7% N/A
5 Yr N/A* -14.7% 15.3% N/A
10 Yr N/A* -6.2% 15.7% N/A

* Annualized

Total Return Ranking - Calendar

Period IBBQ Return Category Return Low Category Return High Rank in Category (%)
2023 4.7% -53.9% 11.7% N/A
2022 -10.4% -22.3% 18.5% N/A
2021 N/A -4.7% 41.4% N/A
2020 N/A -10.2% 13.1% N/A
2019 N/A -5.7% 26.9% N/A

IBBQ - Holdings

Concentration Analysis

IBBQ Category Low Category High IBBQ % Rank
Net Assets 26.7 M 732 K 46.2 B 81.42%
Number of Holdings 226 21 473 2.62%
Net Assets in Top 10 18.7 M 2.18 K 21.6 B 74.35%
Weighting of Top 10 71.46% 12.3% 80.8% 17.80%

Top 10 Holdings

  1. Invesco Private Prime Fund 19.07%
  2. Vertex Pharmaceuticals Inc. 8.74%
  3. Regeneron Pharmaceuticals, Inc. 8.66%
  4. Invesco Private Government Fund 7.78%
  5. Amgen Inc. 7.49%
  6. Gilead Sciences, Inc. 6.94%
  7. AstraZeneca PLC, ADR 3.66%
  8. Moderna, Inc. 3.61%
  9. Biogen Inc. 3.23%
  10. Illumina, Inc. 2.28%

Asset Allocation

Weighting Return Low Return High IBBQ % Rank
Stocks
99.93% 85.37% 106.13% 1.57%
Cash
26.85% -0.10% 9.01% 100.00%
Preferred Stocks
0.00% 0.00% 7.86% 60.73%
Other
0.00% -22.99% 3.38% 62.30%
Convertible Bonds
0.00% 0.00% 0.37% 60.73%
Bonds
0.00% 0.00% 12.39% 60.21%

Stock Sector Breakdown

Weighting Return Low Return High IBBQ % Rank
Utilities
0.00% 0.00% 0.00% 58.64%
Technology
0.00% 0.00% 22.69% 62.30%
Real Estate
0.00% 0.00% 7.13% 61.78%
Industrials
0.00% 0.00% 7.02% 61.78%
Healthcare
0.00% 59.26% 100.00% 32.46%
Financial Services
0.00% 0.00% 1.85% 72.25%
Energy
0.00% 0.00% 0.00% 58.64%
Communication Services
0.00% 0.00% 9.11% 61.26%
Consumer Defense
0.00% 0.00% 25.73% 62.30%
Consumer Cyclical
0.00% 0.00% 14.20% 60.73%
Basic Materials
0.00% 0.00% 14.83% 71.20%

Stock Geographic Breakdown

Weighting Return Low Return High IBBQ % Rank
US
99.93% 53.67% 104.41% 40.31%
Non US
0.00% 0.00% 45.40% 49.74%

IBBQ - Expenses

Operational Fees

IBBQ Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.19% 0.08% 3.13% 97.94%
Management Fee 0.19% 0.00% 1.25% 3.28%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee N/A 0.03% 0.25% N/A

Sales Fees

IBBQ Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 0.00% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

IBBQ Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 1.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

IBBQ Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover N/A 0.00% 238.00% 9.59%

IBBQ - Distributions

Dividend Yield Analysis

IBBQ Category Low Category High IBBQ % Rank
Dividend Yield 0.78% 0.00% 2.44% 6.12%

Dividend Distribution Analysis

IBBQ Category Low Category High Category Mod
Dividend Distribution Frequency Quarterly Annually Quarterly Annually

Net Income Ratio Analysis

IBBQ Category Low Category High IBBQ % Rank
Net Income Ratio N/A -2.54% 1.92% 11.83%

Capital Gain Distribution Analysis

IBBQ Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Annually

Distributions History

View More +

IBBQ - Fund Manager Analysis

Managers

Peter Hubbard


Start Date

Tenure

Tenure Rank

Jun 09, 2021

0.98

1.0%

Peter Hubbard, Vice President and Director of Portfolio Management of the Invesco PowerShares Capital Management LLC. Mr. Hubbard has been a Portfolio Manager of the Adviser since June 2007 and has been associated with the Adviser since 2005. Prior to joining the Invesco PowerShares Capital Management LLC, Hubbard was a research analyst and trader for Ritchie Capital from September 2003 to May 2005.

Tony Seisser


Start Date

Tenure

Tenure Rank

Jun 09, 2021

0.98

1.0%

Tony Seisser is a Vice President and Portfolio Manager of Invesco PowerShares Capital Management LLC since December 2013. Prior to joining the Adviser, he was employed by Guggenheim Funds Distributors, Inc. where he was a trader from 2010 to 2013. Prior to that, Mr. Seisser was a compliance investigator at the Chicago Board of Options Exchange and Chicago Futures Exchange from 2008 to 2010.

Pratik Doshi


Start Date

Tenure

Tenure Rank

Jun 09, 2021

0.98

1.0%

Pratik Doshi is a Portfolio Manager of Invesco Capital Management. Mr. Doshi has been a Portfolio Manager of Invesco Capital Management since October 2019 and has been associated with Invesco Capital Management since 2018. Prior to joining Invesco Capital Management, Mr. Doshi was a business student in the MBA program at the University of Chicago from 2016 to 2018. From 2014 to 2016, he served as a Vice President at Bank of America, and from 2007 to 2014 he served as Assistant Vice President at Barclays Capital.

Michael Jeanette


Start Date

Tenure

Tenure Rank

Jun 09, 2021

0.98

1.0%

Michael Jeanette, Senior Portfolio Manager of Invesco Capital Management LLC, has been associated with Invesco Capital Management LLC since 2008. Prior to joining Invesco Capital Management LLC, Mr. Jeanette was a trust advisor and GM of Chicago based Richard Lamb, LLC from 1998 to 2007.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.02 24.72 7.26 2.12